Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Wait for pullback to $292.53. Below 200-day MA (death cross); also weak momentum — blocks BUY_NOW at $295.51. Engine's entry $292.53 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Leverage penalty (D/E 2.8): -1.5; Below 200-MA, MA slope -2.2%/30d (confirmed downtrend).
Alnylam is a global commercial-stage biopharmaceutical company with six approved RNAi medicines, generating $2.99B in net product revenues in 2025. AMVUTTRA (vutrisiran) is the dominant revenue driver following its cardiomyopathy approval in March 2025; the company also earns... Read more
Wait for pullback to $292.53. Below 200-day MA (death cross); also weak momentum — blocks BUY_NOW at $295.51. Engine's entry $292.53 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Leverage penalty (D/E 2.8): -1.5; Below 200-MA, MA slope -2.2%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 60. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.52, quality 8.1/10, growth 10.0/10). Score 6.6/10, moderate confidence.
Passes 8/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 58d clear, semi cycle peak clear, materials cycle peak clear). Fails on death cross (50MA < 200MA). Suitability: moderate.
Recent developments
updated 2026-06-01Recent Developments — Alnylam Pharmaceuticals, Inc.
Latest news
- NEWS Alnylam (ALNY) Q1 earnings preview: What you should know beyond the headline estimates - MSN — MSN neutral
- NEWS Alnylam (ALNY) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance — Yahoo Finance neutral
- NEWS ALNY Earnings Preview: Alnylam Q1 2026 on April 30 - Meyka — Meyka neutral
- NEWS Alnylam Shareholders Reaffirm Board, Pay Practices and Auditor - TipRanks — TipRanks neutral
- NEWS RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $445 - Moomoo — Moomoo positive
Generated 2026-06-03T19:31:50Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $292.53. Below 200-day MA (death cross); also weak momentum — blocks BUY_NOW at $295.51. Engine's entry $292.53 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Leverage penalty (D/E 2.8): -1.5; Below 200-MA, MA slope -2.2%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 60. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.52, quality 8.1/10, growth 10.0/10). Target $401.23 (+35.8%), stop $274.14 (−7.8%), Setup A.R:R 8.6:1. Score 6.6/10, moderate confidence.
Take-profit target: $401.23 (+38.9% upside). Target $401.23 (+35.8%), stop $274.14 (−7.8%), Setup A.R:R 8.6:1. Stop-loss: $274.14.
Leverage penalty (D/E 2.8): -1.5; Below 200-MA, MA slope -2.2%/30d (confirmed downtrend).
Alnylam Pharmaceuticals, Inc. trades at a P/E of 75.7 (forward 21.7). TrendMatrix value score: 5.6/10. Verdict: Buy (Wait for Entry).
36 analysts cover ALNY with a consensus score of 3.9/5. Average price target: $446.
What does Alnylam Pharmaceuticals, Inc. do?Alnylam is a global commercial-stage biopharmaceutical company with six approved RNAi medicines, generating $2.99B in...
Alnylam is a global commercial-stage biopharmaceutical company with six approved RNAi medicines, generating $2.99B in net product revenues in 2025. AMVUTTRA (vutrisiran) is the dominant revenue driver following its cardiomyopathy approval in March 2025; the company also earns collaboration royalties from Novartis (Leqvio) and Sanofi (Qfitlia).